Evaxion Biotech Shares Climb on Positive Melanoma Vaccine Trial Results

Key Facts

1Evaxion shares surged following the release of positive 3-year clinical trial data for its melanoma vaccine.

Evaxion Biotech shares surged following the release of positive 3-year clinical trial data for its melanoma vaccine. Investing.com reported that the long-term follow-up data provided a strong fundamental catalyst for the stock's price increase on October 19, 2026.

The stock experienced a significant upward move after the company announced the successful efficacy results from its cancer vaccine trials. The price action on October 19, 2026, was driven by investor optimism regarding the long-term clinical prospects of the biotech firm's primary research pipeline.